National assessment of cancer drugs commences

Walkinshaw, Erin
September 2011
CMAJ: Canadian Medical Association Journal;9/20/2011, Vol. 183 Issue 13, pE985
Academic Journal
The article focuses on the pan-Canadian Oncology Drug Review (pCODR), which offers advice for provincial governments in Canada whether to fund new cancer drugs. PCODR executive director Mona Sabharwal says that pCODR evaluates health benefits and cost effectiveness of drugs before making advice. It adds that pCODR review process will quicken availability of new cancer drugs and will benefit both manufacturers and clinicians due to its clearer standards and consistent and comprehensive reviews.


Related Articles

  • Evaluating New Medicines for Use in Australian Hospitals: Lessons from North America. Duguid, Margaret J. // Journal of Pharmacy Practice & Research;Jun2010, Vol. 40 Issue 2, p124 

    Several centres were visited in North America to identify strategies that could improve the processes used by Australian hospitals when evaluating new medicines for clinical and economic benefits. The centres visited included hospitals, a managed care organisation and the Canadian Agency for...

  • Donepezil a smart choice for mild-to-moderate AD in the UK.  // PharmacoEconomics & Outcomes News;5/15/2010, Issue 603, p3 

    The article discusses a study, which demonstrated the health benefits and costs savings associated with the use of donepezil for mild-to-moderately severe Alzheimer's disease (AD) in Great Britain.

  • Everolimus exceeds sunitinib in pNET.  // PharmacoEconomics & Outcomes News;2/18/2012, Issue 647, p9 

    The article focuses on a study which compared the cost effectiveness of everolimus and sunitinib as first-line treatment for patients with advanced pancreatic neuroendocrine tumours (pNET) in the U.S.

  • Ranibizumab cost effective for AMD in Greece.  // PharmacoEconomics & Outcomes News;2/18/2012, Issue 647, p7 

    The article discusses research on the cost effectiveness of ranibizumab for patients with age-related macular degeneration (AMD) in Greece, referencing a study by K. Athanasakis and colleagues published in "Clinical Therapeutics."

  • Rizatriptan worth it in Canada for moderate-to-severe migraine.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p7 

    Discusses research being done on the cost efficiency of using rizatriptan in the treatment of migraine. Reference to a study by M. Thompson and colleagues, published in a 2005 issue of the journal "PharmacoEconomics"; Effectiveness of rizatriptan in treating migraine; Costs associated with the...

  • Eptacog alfa cost effective for bleeding control in trauma care?  // PharmacoEconomics & Outcomes News;3/24/2007, Issue 524, p9 

    The article discusses research being done on the cost effectiveness of eptacog alfa in controlling bleeding in patients with blunt trauma injuries in Great Britain. It references a study by S. Morris and colleagues, published in the January 2007 issue of "Anaesthesia." The study found that...

  • Topiramate a worthy intervention for migraine prevention.  // PharmacoEconomics & Outcomes News;1/13/2007, Issue 519, p1 

    The article discusses research being done on the use of topiramate in the prevention of migraine in Great Britain. It references a study by J. S. Brown and colleagues, published in the December 2006 issue of "Cephalalgia." The methodology of the study is described. The study concluded that...

  • German system nicer than NICE's.  // PharmacoEconomics & Outcomes News;1/9/2010, Issue 594, p10 

    The article reports on the launch of a new drug evaluation system by the Institute for Quality and Efficiency in Health Care (IQWiG) in Cologne, Germany. Patients cannot be deprived access to health technologies under the social healthcare system in the country. An efficiency frontier graph...

  • Cost-effectiveness of treating multidrug-resistant tuberculosis. Resch, Stephen C.; Salomon, Joshua A.; Murray, Megan; Weinstein, Milton C. // PLoS Medicine;Jul2006, Vol. 3 Issue 7, pe241 

    Background: Despite the existence of effective drug treatments, tuberculosis (TB) causes 2 million deaths annually worldwide. Effective treatment is complicated by multidrug-resistant TB (MDR TB) strains that respond only to second-line drugs. We projected the health benefits and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics